

Hyaluronidase Market is Set to Generate Sales of US\$ 1,894.03 Million By 2031 | Astute Analytica

DDDDDD DD DDDD DDDDDDD DDDDD@https://www.astuteanalytica.com/requestsample/hyaluronidase-market

The global hyaluronidase market, an enzyme that breaks down hyaluronic acid, is experiencing consistent expansion in demand, supply, and consumption. The



expanding prevalence of skin-related illnesses and the growing demand for dermatological treatments drive the demand for the global market. Furthermore, hyaluronidase is employed in several medical applications, which contributes to global market growth. The supply is also expanding, as companies invest in research & development to bring new and creative products to market.

The market under consideration is expanding as more corrective procedures include hyaluronidase and more people seek minimally invasive cosmetic treatments. For example, in December 2022, according to an article in the journal Aesthetic Plastic Surgery, hyaluronidase therapy can repair fillers that were given too much and can assist dissolve subcutaneous nodules. Dermatologists can use hyaluronidase to repair and reverse the results of unsuccessful hyaluronic acid-based filler treatments. As a result of these advantages, the demand for hyaluronidase is always increasing, fueling the expansion of the market.

A rise in public awareness of cosmetic operations is raising demand for hyaluronidase and driving the expansion of the global market. Cosmetic operations are in high demand all over the world. For example, according to a survey performed in 2021 by the Menarini Group, an Italian pharmaceutical company, 37% of respondents had noticed a rise in demand for aesthetic

procedures since the commencement of the global COVID-19 epidemic, owing to the desire to look good on social media.

The animal-derived hyaluronidase sector has contributed significantly to the global market, accounting for more than \$495.34 million in 2022. This segment is expected to continue dominating in the coming years.

The majority of hyaluronidase approved and sold comes from animal sources. As a result, animal-based hyaluronidase has a large market share. Bovine and porcine are two of the most common animal sources. Manufacturers' brands include Hydase (PrimaPharma), Vitrase (Bausch & Lomb Incorporated), and Amphadase (Amphastar Pharmaceuticals, Inc.).

Furthermore, the fact that animal-based hyaluronidase is superior to synthetic varieties is likely to aid the growth of the examined section. According to an article released by the NCBI in April 2021, more than 107,000 dermal filler procedures are performed in the United States each year. As a result, a significant number of dermal filler procedures are projected to raise the need for hyaluronidase from animals, which will aid in the growth of this segment.

North America is the largest hyaluronidase market, accounting for more than US\$ 306.13 million of the global market in 2022. The United States and Canada are key revenue generators in the region. In 2022, the United States contributed about US\$ 277 million, accounting for approximately 90% of the regional market share. Canada also contributes significantly to the North American hyaluronidase market, with approximately \$28.30 million in 2022.

North America is likely to have a large part of the global market due to the large number of large companies that manufacture these goods, the large number of people who utilize advanced therapies, and the numerous dermatology clinics that prescribe these treatments. The fact that healthcare expenses are rising and that there is a well-established healthcare infrastructure is also very favorable to the regional market's overall progress.

The market is expanding as more people get cosmetic surgery. For instance, the Aesthetic Society reported in January 2022 that surgical operations increased by 54% in the United States in 2021, while non-surgical procedures increased by 44%. As a result, the high number of non-surgical treatments performed in the United States is growing demand for hyaluronidase and driving the expansion of the regional market.

Significant competitors in the sector include Halozyme Therapeutics, Baxter International, and Pfizer Inc., which is expected to drive market growth. Demand for hyaluronidase is expected to rise as the region's trend toward minimally invasive surgery continues.

The market for hyaluronidase is moderately competitive, with a few large players. Several key industry players and research institutions are actively participating in the advancement of the hyaluronidase field. PrimaPharma, Inc, Amphastar Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Halozyme, Inc., and Sun Pharmaceutical Industries Ltd are the leading players in the global market. These organizations invest heavily in research and development to introduce innovative products and enhance treatment protocols.

$0000\ 00\ 000000000\ 0000000$

- Bausch & Lomb Incorporated
- McKesson
- Amphastar Pharmaceuticals Inc.
- · Halozyme Inc.
- the Cooper Companies Inc.
- Sun Pharmaceutical Industries Ltd.
- STEMCELL Technologies Inc.
- Shreya Life Sciences Pvt. Ltd.
- Calzyme
- Dermax Medical Technology (Hebei) Co., Ltd.
- Shijiazhuang Yiang Technology Co., Ltd.
- Xiamen Vecon Int
- Other Prominent Players

- Animal Derived
- Synthetic

By Application

- Dermatology
- Chemotherapy
- Ophthalmology
- Plastic Surgery
- Others

5 THE 6.5.
o Canada
o Mexico
• Europe
Western Europe
☐ The UK
☐ Germany
□ France
□ Italy
□ Spain
o Rest of Western Europe
Eastern Europe
Poland
□ Russia
o Rest of Eastern Europe
Asia Pacific
o China
o India
o Japan
o Australia & New Zealand
o South Korea
o ASEAN
o Rest of Asia Pacific
Middle East & Africa
o Saudi Arabia
o South Africa
o UAE
o Rest of MEA
South America
o Argentina
o Brazil
o Rest of South America
0000000 000000 00000 00 00000000 000000
https://www.astuteanalytica.com/request-sample/hyaluronidase-market

By Region

o The U.S.

North America

Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth, and uncannily accurate estimates and projections

for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the globe.

They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron-come at the top. You can be sure of the best cost-effective, value-added package from us, should you decide to engage with us.

Aamir Beg Astute Analytica +1 888-429-6757 email us here Visit us on social media: Twitter LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/649375647

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.